What are the NCCN treatment guidelines for soft-tissue angiosarcoma (AS)?

Updated: Sep 04, 2018
  • Author: Maria Belén Carsi, MD, PhD, FRCS; Chief Editor: Edwin Choy, MD, PhD  more...
  • Print

For stage I angiosarcomas, the National Comprehensive Cancer Network (NCCN) recommends surgery to obtain adequate oncologic margins. For stage II and stage IIIA and IIIB disease that can be resected with acceptable functional outcomes, the NCCN also recommends preoperative radiation therapy (category 1). For stage IIIA-B disease, category 2B recommendations include preoperative chemoradiation or chemotherapy, and postoperative chemoradiation. [21] The NCCN lists the following combination regimens as having activity against angiosarcoma:

  • AD (doxorubicin, dacarbazine) 
  • AIM (doxorubicin, ifosfamide, mesna)
  • MAID (mesna, doxorubicin, ifosfamide, dacarbazine)
  • Ifosfamide, epirubicin, mesna
  • Gemcitabine and docetaxel
  • Gemcitabine and vinorelbine
  • Gemcitabine and dacarbazine
  • Doxorubicin and olaratuma

The NCCN lists the following single agents as having activity against angiosarcoma:

  • Doxorubicin
  • Ifosfamide
  • Epirubicin
  • Gemcitabine
  • Dacarbazine
  • Liposomal doxorubicin
  • Temozolomide
  • Vinorelbine
  • Eribulin
  • Trabectedin
  • Pazopanib

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!